Inside the Chinese Chemical Firm That Fed the U.S. Fentanyl Supply Chain
Two former executives of Hubei Amarvel Biotech were sentenced in New York for importing fentanyl precursor chemicals, exposing a global supply chain that stretches from Chinese labs to U.S. streets.
The fentanyl crisis in the United States has long been treated as a domestic overdose emergency. A series of recent convictions in New York shows that it is also a global chemical trade story, with roots in Chinese manufacturing, money laundering, and an undercover operation on the other side of the world.
Qingzhou Wang and Yiyi Chen, two former executives at Hubei Amarvel Biotech, a chemicals company based in Wuhan, were sentenced to 25 and 15 years in prison respectively for conspiring to import fentanyl precursor chemicals and launder the proceeds. Their case marks the first time Chinese nationals accused of fentanyl-related trafficking have been extradited from overseas to face trial in the United States.
From online ads to a Fiji sting
According to court documents, Amarvel Biotech openly advertised precursor chemicals online, targeting buyers in the United States and Mexico. The company allegedly marketed substances used to manufacture fentanyl, the synthetic opioid that now ranks as the leading cause of death for Americans aged 18 to 49.
The investigation took a dramatic turn in June 2023, when Wang and Chen traveled to Fiji. They were arrested there in a Drug Enforcement Administration-led operation and later expelled to the United States, where they were indicted in the Southern District of New York. Prosecutors said one shipment alone involved roughly 200 kilograms of chemicals, enough to produce an estimated 25 million lethal doses.
Convictions and sentences
A federal jury in New York convicted both defendants in February 2025. In August, Chen received a 15-year sentence. Wang, described as the company’s principal executive, was sentenced to 25 years in September. Prosecutors argued the executives treated a legitimate chemical business as a front for shipping the building blocks of a deadly drug.
A supply chain that crosses borders
The case illustrates how fentanyl production depends on a dispersed international supply chain. Precursor chemicals often leave China, are processed into fentanyl in Mexico, and then are smuggled across the U.S. border in counterfeit pills. Disrupting that chain means coordinating law enforcement, customs, and financial investigators across multiple countries.
Washington has repeatedly pressed Beijing to tighten controls on precursor exports. Chinese authorities have placed additional fentanyl-related substances under regulation, but U.S. officials say enforcement remains uneven and that some Chinese firms continue to ship restricted chemicals with little transparency.
What it means for markets and policy
For Global Economic Review readers, the Amarvel Biotech case is a reminder that the opioid crisis carries measurable economic costs: lost productivity, health-care spending, and the price of policing a transnational trade. It also raises questions about corporate accountability in sectors where chemicals can move easily between legitimate and illicit uses.
As both the Biden and Trump administrations have used sanctions and indictments to target the trade, the verdicts in New York are likely to encourage more cross-border prosecutions. Whether that translates into fewer overdoses will depend on whether regulators can keep pace with a supply chain that operates across continents and currencies.
